PrEP: PREP (Pre-Exposure Prophylaxis) of COVID-19
Study Details
Study Description
Brief Summary
This is a study of immunocompromised individuals who have received or plan to receive a drug called EVUSHELD. This study is looking at any serious adverse events that might happen after receiving EVUSHELD, the levels of EVUSHELD in participant's blood, blood antibody levels, neutralizing antibodies against SARS-CoV-2 (the virus that causes COVID-19), and other blood responses related to the immune system and COVID-19. Investigators are collecting blood and may also collect other samples such as nose swabs, oral swabs, or saliva.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
This is a prospective study of 500 immunocompromised participants at UPMC health system. EVUSHELD will be given according to the EUA in the United States as a part of standard of care by the patient's health care provider. Patients who receive intramuscular EVUSHELD as standard of care will be enrolled and followed for 12-months. The target sample size is 500 immunocompromised individuals; serum concentrations of AZD7442 will be obtained in all patients at the 6 (or at enrollment if the time point has passed) and 12 month timepoints.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Outpatients Outpatients who have not yet received EVUSHELD but who plan on receiving it in the future. |
Drug: Evusheld
Participants who have received or plan to receive Evusheld.
|
| Select inpatients (SOT/HCT/CAR-T) Newly transplanted adult solid organ transplant and HCT recipients, as well as CAR-T-cell therapy recipients, during their hospitalization to undergo SOT/HCT/CAR-T-cell therapy |
Drug: Evusheld
Participants who have received or plan to receive Evusheld.
|
| Individuals who have received EVUSHELD Individuals who have received EVUSHELD within 9 months of enrollment. |
Drug: Evusheld
Participants who have received or plan to receive Evusheld.
|
Outcome Measures
Primary Outcome Measures
- Concentration of AZD7442 in serum over time [ENROLLMENT, 6 MONTHS, 12 MONTHS] Concentration of AZD7442 in serum over time [ENROLLMENT, 6 MONTHS, 12 MONTHS] Concentration of AZD7442 in serum over time [ENROLLMENT, 6 MONTHS, 12 MONTHS] [12-months]
The primary objective of PrEP C-19 is to measure AZD7442 serum concentration levels by blood draws at 6 months (or at enrollment if the time point has passed) and 12 months after IM administration of EVUSHELD.
Secondary Outcome Measures
- Concentration of AZD7442 in serum [12-months]
Collected at 1, 3, AND 9 months
- Assessment of SARS-CoV-2 Spike IgG levels using Bioplex/Biorad assays, viral neutralization assay using competitive ACE2 EIA, and pseudovirus neutralization titers [12-months]
Collected at enrollment and 1, 3, 6, 9, and 12 months
- Assessment of T-cell responses using an ELISPOT assay [12-months]
Obtained before and after vaccination
- Determining SARS_CoV-2 variant type using whole genome sequencing [12-months]
Collected among subjects with breakthrough infection
- Determining Concentration of AZD7442 in serum, SARS-CoV-2 Spike IgG levels using Bioplex/Biorad assays, viral neutralization assay using competitive ACE2 EIA, and pseudovirus neutralization titers [12-months]
Collected during breakthrough infection
- Proportion of participants with ≥1 COVID-19-related medically-attended visit [12-months]
Participants with ≥1 COVID-19-related medically-attended visit
- Proportion of participants who die by the end of the study [12-months]
COVID-19 associated and all-cause mortality
- Lifestyle Modification Questionnaire [12-months]
Proportion of participants who report changes in lifestyle
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥ 12 and at least 40 kg
-
Eligible for EVUSHELD as per the EUA
Exclusion Criteria:
-
Active and confirmed COVID-19
-
Known or suspected pregnancy, concurrent lactation
-
Any other significant disease, disorder, or finding, in the opinion of the investigator, that may significantly increase the risk to the participant because of participation in the study, affect the ability of the subject to participate in the study, or impair interpretation of the study data
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | UPMC | Pittsburgh | Pennsylvania | United States | 15213 |
Sponsors and Collaborators
- Ghady Haidar
- AstraZeneca
Investigators
- Principal Investigator: Ghady Haidar, MD, Assistant Professor
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PrEP C-19